Correlation Engine 2.0
Clear Search sequence regions

  • adult (2)
  • cannabinoid (3)
  • cognitive (1)
  • drug effect (2)
  • drug screens (2)
  • emotions (1)
  • euphoria (1)
  • human (2)
  • impairment (1)
  • isomer (1)
  • phase (4)
  • placebo (3)
  • signal (1)
  • tetrahydrocannabinol (3)
  • volunteers (1)
  • Sizes of these terms reflect their relevance to your search.

    Introduction: Tetrahydrocannabivarin (THCV) is an understudied cannabinoid that appears to have effects that vary as a function of dose. No human study has evaluated the safety and nature of effects in a wide range of THCV doses. Methods: This was a two-phase, dose-ranging, placebo-controlled trial of the Δ8 isomer of oral THCV in healthy adults. Phase 1 utilized an unblinded, single-ascending dose design (n=3). Phase 2 used a double-blind, randomized, within-participant crossover design (n=18). Participants received single acute doses of placebo and 12.5, 25, 50, 100, and 200 mg of THCV. Safety measures and subjective and cognitive effects were assessed predose and up to 8 h postdose. Results: Most adverse events (AEs; 55/60) were mild. Euphoric mood was the most common AE. The 12.5, 25, and 200 mg doses produced significantly lower minimum times to complete the digit vigilance test (ps=0.01). The 25 mg dose showed elevations on mean ratings of "energetic" at 1-, 2-, and 4-h postdose, but the maximum postdose rating for this dose did not achieve statistical significance relative to placebo ([95% confidence interval]=3.2 [-0.5 to 6.9], p=0.116). The 100 and 200 mg doses showed elevations on ratings of "feel a drug effect" and "like the drug effect." Almost all urine drug screens (78/79) at 8 h postdose in the active THCV conditions tested positive for tetrahydrocannabinol (THC). Conclusion: All THCV doses displayed a favorable safety profile. Several THCV doses showed a preliminary signal for improved sustained attention, but the effect was not dose dependent. Though mild and not associated with impairment, THC-like effects were observed at higher THCV doses. Oral THCV-containing products could lead to positive urine drug screens for THC. ID: NCT05210634.


    Erica N Peters, Laura MacNair, Amy Harrison, Matthew T Feldner, Graham M L Eglit, Shanna Babalonis, Cynthia Turcotte, Marcel O Bonn-Miller. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. Cannabis and cannabinoid research. 2023 Sep;8(S1):S71-S82

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37721990

    View Full Text